Teknova Q3 revenue $10.5M (+9% YoY); net loss narrows to $4.3M; reaffirms FY2025 guidance

Alpha Teknova, Inc.

2025-Q3 EPS reported -$0.23 revenue$30,536,000

Revenue $10.5M, up 9% from Q3 2024; Lab Essentials $8.3M (+16%), Clinical Solutions $1.7M (-13%).
Gross margin 30.7% vs 0.9% (Q3 2024); prior year included $2.8M non-recurring inventory charges.
Net loss $4.3M ($0.08/share) vs $7.6M ($0.15/share) a year ago; Adjusted EBITDA -$1.6M vs -$5.0M.
Free Cash Outflow $2.4M, flat YoY. Cash & short-term investments $22.1M; borrowings $13.2M.
Reaffirms FY2025 revenue guidance $39-42M and Free Cash Outflow <$12M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.